Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,681.12
(
-0.52%
)
US TECH 100
24,037.60
(
-0.39%
)
Dow Jones
46,600.70
(
-0.84%
)
Brent Oil
105.45
(
4.77%
)
Bitcoin
71,254.96
(
-3.64%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: biomaven0 post# 106919

Thursday, 10/21/2010 5:03:10 PM

Thursday, October 21, 2010 5:03:10 PM

Post# of 257253
I agree with you to a degree, Peter. However, there is no pressing reason to approve Bydureon immediately. There are Byetta, Victoza already on the market. It's not going to be approved unlesss the question is resolved. As one FDA official said, the 3rd and 4th drug in the same class are tougher to get approved.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now